Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 05:10 ET | Source: Novo Nordisk A/S

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need